var data={"title":"Factor VIII, recombinant human: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor VIII, recombinant human: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5650?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-viii-recombinant-human-drug-information\" class=\"drug drug_general\">see &quot;Factor VIII, recombinant human: Drug information&quot;</a> and <a href=\"topic.htm?path=factor-viii-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor VIII, recombinant human: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135784\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Advate;</li>\n      <li>Afstyla;</li>\n      <li>Helixate FS;</li>\n      <li>Kogenate FS;</li>\n      <li>Kogenate FS Bio-Set;</li>\n      <li>Kovaltry;</li>\n      <li>Novoeight;</li>\n      <li>Nuwiq;</li>\n      <li>Recombinate;</li>\n      <li>Xyntha;</li>\n      <li>Xyntha Solofuse</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135785\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Advate;</li>\n      <li>Helixate FS;</li>\n      <li>Kogenate FS;</li>\n      <li>Kovaltry;</li>\n      <li>Nuwiq;</li>\n      <li>Xyntha;</li>\n      <li>Xyntha Solofuse</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051146\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihemophilic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11432529\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment</b>; for every 1  international unit per kg body weight of rAHF administered, factor VIII level should increase by 2% (or 2 units/dL); calculated dosage should be adjusted to the actual vial size</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Control or prevention of bleeding in patients with factor VIII deficiency (hemophilia A):</b> IV: Dosage is expressed in units of factor VIII activity (ie, international units) and must be individualized based on formulation, severity of factor VIII deficiency, extent and location of bleed, and clinical situation of patient. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Formula for units required to raise blood level: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Number of Factor VIII Units required = body weight (in kg) x 0.5 units/kg per units/dL x desired factor VIII level increase (units/dL or %) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For example, for a desired 100% level in a 3 kg patient who has an actual level of 20%: Number of Factor VIII Units needed = 3 kg x 80% x 0.5 units/kg per units/dL = 120 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer's labeling:</i>  Advate, Helixate FS, Kogenate FS, Recombinate: Desired Factor VIII level, dosing interval, and duration based on hemorrhage type: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Minor hemorrhage (early joint hemorrhage, mild muscle or oral bleed): 10-20  units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Desired factor VIII levels (% or units/dL): 20-40 </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Frequency of dosing: Every 8-24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Duration of treatment: 1-3 days until bleeding is resolved or healing achieved; mild, superficial, or early hemorrhages may respond to a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate hemorrhage (intramuscular bleed, hematoma, moderate bleeding into oral cavity, definite joint bleed, and known trauma): 15-30 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Desired factor VIII levels (% or units/dL): 30-60 </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Frequency of dosing: Every 8-24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Duration of treatment: &ge;3 days until bleeding, pain, and disability are resolved or healing is achieved</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe/life-threatening hemorrhage (GI, intracranial, intra-abdominal, intrathoracic bleeding, retroperitoneal, retropharyngeal, illiopsoas, CNS bleeding or head trauma, fractures): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Helixate FS, Kogenate FS:</i>  Initial: 40-50  units/kg; maintenance: 20-25 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired factor VIII levels (% or units/dL): 80-100 </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Frequency of dosing: Every 8-12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Duration of treatment: Until bleeding is resolved (duration not specified)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Advate, Recombinate:</i> 30-50 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired factor VIII levels (% or units/dL): 60-100 </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Frequency of dosing: Every 6-12 hours (Advate) or every 8-24 hours (Recombinate) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Duration of treatment: Until bleeding is resolved (duration not specified)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perioperative management:</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Minor surgery (including dental extractions):  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Advate:</i> 30-50 units/kg as bolus infusion beginning within 1 hour prior to surgery; for dental procedures, adjunctive therapy may be considered</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired factor VIII levels (% or units/dL): 60-100 </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Frequency of dosing: Every 12-24 hours as needed to control bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Duration of treatment: Until bleeding is resolved (duration not specified)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Helixate FS, Kogenate FS:</i> 15-30 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired factor VIII levels (% or units/dL): 30-60 </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Frequency of dosing: Every 12-24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Duration of treatment: Until bleeding is resolved (duration not specified) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Recombinate:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired factor VIII levels (% or units/dL): 60-80 </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Frequency of dosing: Single dose plus oral antifibrinolytic therapy within 1 hour is sufficient for most cases</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Major surgery (tonsillectomy, hernia repair, intracranial, intra-abdominal, or intrathoracic surgery; joint replacement, trauma): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Advate:</i> 40-60 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired factor VIII levels (% or units/dL): Pre- and postoperative levels: 80-120; verify 100% activity has been achieved prior to surgery </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Frequency of dosing: Every 6-24 hours as needed </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Duration of treatment: Based on desired level and state of healing  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Helixate FS, Kogenate FS:</i> 50 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired factor VIII levels (% or units/dL): Pre- and postoperative levels: 100; verify 100% activity has been achieved prior to surgery </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Frequency of dosing: Every 6-12 hours as needed </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Duration of treatment: Until healing is complete (~10-14 days)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Recombinate: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired factor VIII levels (% or units/dL): Pre- and postoerative: 80-100</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Frequency of dosing: Every 8-24 hours depending on state of healing </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Routine prophylaxis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Advate:</i> 20-40 units/kg/dose every other day (3-4 times weekly). Alternatively, an every-third-day dosing regimen may be used to target factor VIII trough levels of &ge;1%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Helixate FS, Kogenate FS:</i> <b>Note:</b> For use in patients with no pre-existing joint damage: 25  units/kg/dose given every other day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051139\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=factor-viii-recombinant-human-drug-information\" class=\"drug drug_general\">see &quot;Factor VIII, recombinant human: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment</b>; for every 1 international unit per kg body weight of rAHF administered, factor VIII level should increase by 2% (or 2 units/dL); calculated dosage should be adjusted to the actual vial size </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Control or prevention of bleeding in patients with factor VIII deficiency (hemophilia A):</b> IV: Infants, Children, and Adolescents: Dosage is expressed in units of factor VIII activity (ie, international units) and must be individualized based on formulation, severity of factor VIII deficiency, extent and location of bleed, and clinical situation of patient. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Formula for units required to raise blood level:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Number of Factor VIII Units required = body weight (in kg) x 0.5 units/kg per units/dL x desired VIII level increase (units/dL or %) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">For example, for a desired 100% level in a 25 kg patient who has an actual level of 20%: Number of Factor VIII Units needed = 25 kg x 80% x 0.5 units/kg per units/dL = 1000 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i> Advate, Helixate FS, Kogenate FS, Recombinate, Xyntha: Desired factor VIII level, dosing interval, and duration based on hemorrhage type: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Minor hemorrhage (early joint hemorrhage, mild muscle or oral bleed): 10-20 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Desired factor VIII levels (% or units/dL): 20-40 </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Frequency of dosing: Every 8-24 hours (Advate: &lt;6 years old) <b>or</b> every 12-24 hours (Advate: &ge;6 years old; Helixate FS; Kogentae FS; Xyntha) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Duration of treatment: 1-3 days until bleeding is resolved or healing achieved; mild, superficial, or early hemorrhages may respond to a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate hemorrhage (intramuscular bleed, hematoma, moderate bleeding into oral cavity, definite joint bleed, and known trauma): 15-30  units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Desired factor VIII levels (% or units/dL): 30-60 </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Frequency of dosing: Every 8-24 hours (Advate: &lt;6 years old) <b>or</b> every 12-24 hours (Advate: &ge;6 years old; Helixate FS; Kogenate FS; Xyntha) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Duration of treatment: &ge;3 days until bleeding, pain, and disability are resolved or healing is achieved</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe/life-threatening hemorrhage (GI, intracranial, intra-abdominal, intrathoracic bleeding, retroperitoneal, retropharyngeal, illiopsoas, CNS bleeding or head trauma, fractures): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Helixate FS, Kogenate FS:</i>  Initial: 40-50 units/kg; maintenance: 20-25 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Desired factor VIII levels (% or units/dL): 80-100 </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequency of dosing: Every 8-12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Duration of treatment: Until bleeding is resolved (duration not specified)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Advate, Recombinate, Xyntha:</i> 30-50 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Desired factor VIII levels (% or units/dL): 60-100 </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequency of dosing: Every 6-12 hours (Advate: &lt;6 years old) <b>or</b> 8-24 hours (Advate: &ge;6 years old; Recombinate; Xyntha) </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Duration of treatment: Until bleeding is resolved (duration not specified)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternative dosing:</i>  <b> Note:</b> The following recommendations reflect guideline recommendations for general dosing requirements; may vary from those found within prescribing information or practitioner preference: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Infants, Children, and Adolescents: Desired factor VIII level to maintain and duration based on site of hemorrhage/clinical situation (when no significant resource constraints exist) [WFH guidelines (Srivastava, 2013)]. <b>Note:</b> Factor VIII level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels before the next dose.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Joint: 40-60 units/dL for 1-2 days; may be longer if response is inadequate </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Superficial muscle (no neurovascular compromise): 40-60 units/dL for 2-3 days, sometimes longer if response is inadequate </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss: Initial: 80-100 units/dL for 1-2 days; Maintenance: 30-60 units/dL for 3-5 days, sometimes longer as secondary prophylaxis during physiotherapy </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CNS/head: Initial: 80-100 units/dL for 1-7 days; Maintenance: 50 units/dL for 8-21 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Throat and neck: Initial: 80-100 units/dL for 1-7 days; Maintenance: 50 units/dL for 8-14 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Gastrointestinal: Initial: 80-100 units/dL for 7-14 days; Maintenance: 50 units/dL (duration not specified) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Renal: 50 units/dL for 3-5 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Deep laceration: 50 units/dL for 5-7 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: Infants, Children, and Adolescents: Limited data available: <b>Note:</b> For patients who require prolonged periods of treatment (eg, intracranial hemorrhage or surgery) to avoid peaks and troughs associated with intermittent infusions [Batorova, 2002; Poon, 2012; WFH guidelines (Srivastava, 2013)]: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Following initial bolus to achieve the desired factor VIII level: Initial dosing: 2-4 units/kg/hour; adjust dose based on frequent factor VIII assays and calculation of factor VIII clearance at steady-state using the following equations: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Factor VIII clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) / (plasma Factor  level in units/<b>mL</b>) </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">New infusion rate (units/kg/hour) = (factor VIII clearance in mL/kg/hour) x (desired plasma level in units/<b>mL</b>) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Perioperative management:</b> IV: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i> Desired factor VIII level, dosing interval, and duration based on surgery type: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Minor surgery (including dental extractions):  </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Advate: </i>30-50 units/kg as bolus infusion beginning within 1 hour prior to surgery; for dental procedures, adjunctive therapy may be considered</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Desired factor VIII levels (% or units/dL): 60-100 </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequency of dosing: Every 12-24 hours as needed to control bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Duration of treatment: Until bleeding is resolved (duration not specified)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Helixate FS, Kogenate FS, Xyntha:</i> 15-30 units/kg/dose; for dental procedures, a single dose plus oral antifibrinolytic therapy within 1 hour may be sufficient</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Desired factor VIII levels (% or units/dL): 30-60 </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequency of dosing: Every 12-24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Duration of treatment: 3-4 days or until bleeding is resolved</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Recombinate:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Desired factor VIII levels (% or units/dL): 60-80</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequency of dosing: Single dose plus oral antifibrinolytic therapy within 1 hour is sufficient for most cases </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Major surgery (tonsillectomy, hernia repair, intracranial, intra-abdominal or intrahtoracic surgery; joint replacement, trauma): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Advate:</i> 40-60 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Desired factor VIII levels (% or units/dL): Pre- and postoperative levels: 80-120; verify 100% activity has been achieved prior to surgery </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequency of dosing: Every 6-24 hours (&lt;6 years old) <b>or</b> every 8-24 hours (&ge;6 years old) as needed </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Duration of treatment: Based on desired level and state of healing</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Helixate FS, Kogenate FS:</i> 50 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Desired factor VIII levels (% or units/dL): Pre- and postoperative levels: 100; verify 100% activity has been achieved prior to surgery </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequency of dosing: Every 6-12 hours as needed </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Duration of treatment: Until healing is complete (~10-14 days)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Recombinate:</i> 40-50 units/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Desired factor VIII levels (% or units/dL): Pre- and postoperative: 80-100</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequency of dosing: Every 8-24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Duration of treatment: Based on state of healing </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Xyntha:</i> Children &ge;12 years and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Desired factor VIII levels (% or units/dL): 60-100 </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequency of dosing: Every 8-24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Duration of treatment: Until bleeding is resolved and wound healing is achieved</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternative dosing:</i> <b> Note:</b> The following recommendations reflect guideline recommendations for general dosing requirements; may vary from those found within prescribing information or practitioner preference:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Desired factor VIII level to maintain and duration based on site of hemorrhage/clinical situation (when no significant resource constraints exist) [WFH guidelines (Srivastava, 2013)]. <b>Note:</b> Factor VIII level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels before the next dose.  </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Surgery (major): </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Preop: 80-100 units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Postop: 60-80 units/dL for 1-3 days; then 40-60 units/dL for 4-6 days; then 30-50 units/dL for 7-14 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Surgery (minor):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Preop: 50-80 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Postop: 30-80 units/dL for 1-5 days depending on procedure type </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: Infants, Children, and Adolescents: Limited data available: Initial: 25-50 units/kg prior to surgery, followed by continuous infusion at a rate of 3-5 units/kg/hour; regimen based on two studies evaluating use in pediatric surgery patients (age range: 0.9-17 years); rate was adjusted and additional boluses given as needed to maintain desired factor VIII level (Batorova, 2012; Dingli, 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Routine prophylaxis:</b> IV: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:  </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Advate:</i> 20-40 units/kg/dose every other day (3-4 times weekly). Alternatively, an every-third-day dosing regimen may be used to target factor VIII trough levels of &ge;1%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Helixate FS, Kogenate FS:</i> <b>Note:</b> For use in patients with no pre-existing joint damage: 25 units/kg/dose given every other day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternative dosing:</i> 15-30 units/kg/dose 3 times weekly (WFH guidelines [Srivastava, 2013] [Utrecht protocol]) <b>or</b> 25-40 units/kg/dose 3 times weekly (WFH guidelines [Srivastava, 2013] [Malm&ouml; protocol]) <b>or</b> 25-50 units/kg/dose administered 3 times weekly <b>or</b> every other day (National Hemophilia Foundation, MASAC recommendation, 2007); optimum regimen has yet to be defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemophilia:</b> IV: <b>Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment.</b> In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL (or 2%). (General guidelines presented; consult individual product labeling for specific dosing recommendations.) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage based on desired factor VIII increase (%): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">To calculate dosage needed based on desired factor VIII increase (%): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Body weight (kg) x 0.5 units/kg x desired factor VIII increase (%) = units factor VIII required </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">For example: 50 kg x 0.5 units/kg x 30 (% increase) = 750 units factor VIII </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage based on expected factor VIII increase (%): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">It is also possible to calculate the <b>expected</b> % factor VIII increase: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">(# units administered x 2%/units/kg) divided by body weight (kg) = expected % factor VIII increase </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">For example: (1400 units x 2%/units/kg) divided by 70 kg = 40% </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>General guidelines (consult individual product labeling for specific dosage recommendations): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Minor hemorrhage: 10-20 units/kg as a single dose to achieve FVIII plasma level ~20% to 40% of normal. Mild superficial or early hemorrhages may respond to a single dose; may repeat dose every 12-24 hours for 1-3 days until bleeding is resolved or healing achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate hemorrhage/minor surgery: 15-30 units/kg to achieve FVIII plasma level 30% to 60% of normal. May repeat 1 dose at 12-24 hours if needed. Some products suggest continuing for &ge;3 days until pain and disability are resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\"> Major to life-threatening hemorrhage: Initial dose 30-50 units/kg followed by a maintenance dose of 20-50 units/kg every 8-24 hours until threat is resolved, to achieve FVIII plasma level 60% to 100% of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Minor surgery (including tooth extraction): 15-50 units/kg to raise factor VIII level to ~30% to 100% before procedure/surgery. May repeat every 12-24 hours until bleeding is resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Major surgery: 40-60 units/kg given preoperatively to raise factor VIII level to ~60% to 120% before surgery begins. May repeat as necessary after 6-24 hours until wound healing. Intensity of therapy may depend on type of surgery and postoperative regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If bleeding is not controlled with adequate dose, test for presence of inhibitor. It may not be possible or practical to control bleeding if inhibitor titers &gt;10 Bethesda units/mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135770\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kogenate FS: 250 units, 500 units, 1000 units [contains mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afstyla: 250 units, 500 units, 1000 units, 1500 units, 2000 units, 2500 units, 3000 units [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Helixate FS: 250 units, 500 units, 1000 units, 2000 units, 3000 units [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kogenate FS: 2000 units, 3000 units [contains mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kogenate FS Bio-Set: 250 units, 500 units, 1000 units, 2000 units, 3000 units [contains mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nuwiq: 250 units, 500 units, 1000 units, 2000 units, 2500 units, 3000 units, 4000 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xyntha: 250 units, 500 units, 1000 units, 2000 units [albumin free; contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xyntha Solofuse: 250 units, 500 units, 1000 units, 2000 units, 3000 units [albumin free; contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kovaltry: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advate: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea); 4000 units (1 ea) [albumin free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Novoeight: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nuwiq: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 2500 units (1 ea); 3000 units (1 ea); 4000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Recombinate: 220-400 units (1 ea); 401-800 units (1 ea); 801-1240 units (1 ea); 1241-1800 units (1 ea); 1801-2400 units (1 ea) [contains albumin human, polyethylene glycol, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135756\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573579\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=factor-viii-recombinant-human-drug-information\" class=\"drug drug_general\">see &quot;Factor VIII, recombinant human: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strengths expressed with approximate values.  Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051150\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Parenteral: IV administration only; use administration sets/tubing provided by manufacturer (if provided). Adjust administration rate based on patient response. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Advate: Infuse over &le;5 minutes; maximum infusion rate: 10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Helixate FS, Kogenate FS: Infuse over 1 to 15 minutes; based on patient tolerability; use sterile administration set provided by manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Recombinate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Reconstitution with 5 mL of SWFI: Infuse at a maximum rate of 5 mL/minute </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Reconstitution with 10 mL of SWFI: Infuse at a maximum rate of 10 mL/minute </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Xyntha, Xyntha Solufuse: Infuse over several minutes; adjust based on patient comfort. Do not admix or administer in same tubing as other medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">WFH recommendations: Infuse slowly with maximum rate determined by age: Young children: 100 <b>units</b>/minute; Adults: 3 mL/minute; may also administer as a continuous infusion in select patients (WFH guidelines [Srivastava 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135782\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to reconstitution, store refrigerated at  2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Do not refrigerate after reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Advate: May also be stored at room temperature (not to exceed 30&deg;C [86&deg;F]) up to 6 months; do not return to refrigerator. Use within 3 hours of reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Afstyla: May also be stored at room temperature (not to exceed 25&deg;C [77&deg;F]) up to 3 months; do not return to refrigerator. Store in original package to protect from light. Use within 4 hours of reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Helixate FS, Kogenate FS, Kovaltry: May also be stored at room temperature (not to exceed 25&deg;C [77&deg;F]) up to 12 months; do not return to refrigerator. Protect from extreme exposure to light during storage. Use within 3 hours of reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Novoeight: May also be stored at room temperature (not to exceed 30&deg;C [86&deg;F]) up to 12 months; do not return to refrigerator; after 12 months at room temperature, use immediately or discard. Store in original package to protect from light. Use within 4 hours of reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nuwiq: May also be stored at room temperature (not to exceed 25&deg;C [77&deg;F]) up to 3 months; do not return to refrigerator. Store in original package to protect from light. Use within 3 hours of reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Recombinate: May also be stored at room temperature, not to exceed 30&deg;C (86&deg;F). Use within 3 hours of reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Xyntha: May also be stored at room temperature (not to exceed 25&deg;C [77&deg;F]) up to 3 months; after room temperature storage, product may be returned to the refrigerator until the expiration date; however, do not store at room temperature and return to refrigerator temperature more than once. Avoid prolonged exposure to light during storage. Use within 3 hours of reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Xyntha Solofuse: May also be stored at room temperature not to exceed 25&deg;C [77&deg;F]) up to 3 months; do not return to refrigerator; after 3 months at room temperature, must use immediately or discard. Use within 3 hours of reconstitution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051149\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Antihemophilic Factor (Recombinant) is not indicated for the treatment of von Willebrand disease.</b></p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Advate: Prevention and control of hemorrhagic episodes in patients with hemophilia A; perioperative management of patients with hemophilia A; routine prophylaxis to prevent or reduce the frequency of  bleeding episodes in patients with hemophilia A (All indications: FDA approved in ages 0-16 years and adults)  </p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Helixate FS, Kogenate FS: Prevention and control of hemorrhagic episodes in patients with hemophilia A; perioperative management of patients with hemophilia A; routine prophylaxis to reduce the frequency of bleeding episodes and reduce the risk of joint damage in children with hemophilia A with no pre-existing joint damage (All indications: FDA approved in ages 0-16 years)</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Recombinate: Prevention and control of hemorrhagic episodes in patients with hemophilia A (FDA approved in all ages); perioperative management of patients with hemophilia A (FDA approved in all ages)</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Xyntha: Prevention and control of hemorrhagic episodes in patients with hemophilia A (FDA approved in ages &ge;12 years and adults); perioperative management of patients with hemophilia A (FDA approved in ages &ge;12 years and  adults)</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Has also been used in patients with acquired factor VIII inhibitors &lt;10 Bethesda units/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6814324\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor VIII may be confused with Factor XIII</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Confusion may occur due to the omitting of  &ldquo;Factor VIII&rdquo; from some product labeling. Review product contents carefully prior to dispensing any antihemophilic factor.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135804\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest discomfort, palpitations, sinus tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, headache, insomnia, pain, procedural pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Allergic dermatitis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, abdominal pain, diarrhea, dyspepsia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Increased factor VIII inhibitors, lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes (including in patients previously exposed to factor VIII products)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Catheter infection, injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain (more common in children), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otic infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, nasal congestion, nasopharyngitis, pharyngolaryngeal pain, rhinorrhea, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (including in patients previously exposed to factor VIII products), limb injury</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anorexia, catheter complication (venous catheter access), cold extremities, cyanosis, epistaxis, facial flushing, feeling hot, hematoma, hypotension, limb pain, loss of consciousness, maculopapular rash, malaise, myalgia, paresthesia, tachycardia, tremor, vasodilatation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135776\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis) to antihemophilic factor, mouse or hamster protein (Advate, Afstyla, Helixate FS, Kogenate FS, Kovaltry, Novoeight, Recombinate, Xyntha), bovine protein (Recombinate only), or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135760\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antibody formation: The development of factor VIII antibodies has been reported with antihemophilic factors; monitor for signs of formation of antibodies to factor VIII; may occur at any time but more common in young children with severe hemophilia. Suspect factor VIII antibodies if the plasma factor VIII level does not increase as expected or if bleeding is not controlled after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Allergic hypersensitivity reactions (including anaphylaxis) may occur; discontinue if hypersensitivity symptoms occur and administer appropriate treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Albumin: Recombinate is stabilized using human albumin. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bovine: Recombinate may contain bovine protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Mouse/hamster protein:  Some products may contain trace amounts of mouse or hamster protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sucrose: Some products are stabilized with or may contain sucrose. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; von Willebrand factor: Some products contain naturally-occurring von Willebrand factor for stabilization; however, efficacy has not been established for the treatment of von Willebrand disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dose requirements: The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819745\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">Allergic-type hypersensitivity reactions including anaphylaxis may occur; discontinue therapy immediately if urticaria, hives, hypotension, tightness of the chest, wheezing, or anaphylaxis develop; emergency treatment and resuscitative measures (eg, epinephrine, oxygen) may be needed. Clinical response to antihemophilic factor administration may vary; dosage must be individualized based on coagulation studies (performed prior to treatment and at regular intervals during treatment) and clinical response. If bleeding is not controlled with the recommended dose, determine plasma level of factor VIII and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor VIII fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate. Formation of factor VIII inhibitors (neutralizing antibodies to AHF recombinant) may occur at any time, but is more common in young children with severe hemophilia during the first years of therapy, or in patients at any age who received little prior therapy with factor VIII; monitor patients appropriately.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298758\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218001\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12757&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Emicizumab-kxwh: May enhance the thrombogenic effect of Factor VIII Products.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135766\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135778\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Factor VIII concentrations may increase in pregnant women with coagulation disorders. Pregnant women should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Prophylaxis may be needed if concentrations are &lt;50 units/mL at term and treatment should continue for 3 to 5 days postpartum depending on route of delivery. Because parvovirus infection may cause hydrops fetalis or fetal death, a recombinant product is preferred if prophylaxis or treatment is needed. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Kadir 2009; Lee 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051145\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Bleeding; heart rate and blood pressure (before and during IV administration); factor VIII  levels prior to and during treatment; monitor for the development of inhibitor antibodies by clinical observations (eg, inadequate control of bleeding with adequate doses) and laboratory tests (eg, inhibitor level, Bethesda assay)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051148\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe: Factor level &lt;1% of normal</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate: Factor level 1% to 5% of normal</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild: Factor level &gt;5% to &lt;40% of normal</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135759\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Factor VIII replacement, necessary for clot formation and maintenance of hemostasis. It activates factor X in conjunction with activated factor IX; activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135775\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: ~0.4 to 0.85 dL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advate: Children &lt;12 years: 8.7 to 11.2 hours; Adolescents and Adults: 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Afstyla: Children &lt;12 years: 10.2 to 10.4 hours; Children &ge;12 years and Adolescents: 14.3 hours; Adults: 14.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Helixate FS, Kogenate FS: Children: 10.7 hours; Adults: 13.7 to 14.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kovaltry: Children &lt;12 years: ~12 hours; Children &ge;12 years, Adolescents, and Adults: ~14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Novoeight: Children &lt;12 years: 7.7 to 10 hours; Adolescents and Adults: 11 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nuwiq: Children &le;12 years: 11.9 to 13.1 hours; Adolescents and Adults: 17.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recombinate: Adults: 14.6 &plusmn; 4.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Xyntha, Xyntha Solofuse: Children and Adolescents: 6.9 to 8.3 hours; Adults: 11 to 17 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051154\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">One unit of rAHF is equal to the factor VIII activity present in 1 mL of fresh pooled human plasma. If bleeding is not controlled with adequate dose, test for the presence of factor VIII inhibitor; larger doses of rAHF may be therapeutic with inhibitor titers &lt;10 Bethesda units/mL; it may not be possible or practical to control bleeding if inhibitor titers &gt;10 Bethesda units/mL (due to the very large rAHF doses required); other treatments [eg, antihemophilic factor (porcine), factor IX complex concentrates, recombinant factor VIIa, or anti-inhibitor coagulant complex] may be needed in patients with inhibitor titers &gt;10 Bethesda units/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21121604\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Afstyla Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Helixate FS Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Kogenate FS Bio-Set Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Kogenate FS Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Nuwiq Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Xyntha Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Xyntha Solofuse Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Advate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 unit (Price provided is per AHF Unit): $1.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Kovaltry Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (1): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (1): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (1): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (1): $2.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Novoeight Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $2.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Nuwiq Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 unit (1): $2.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Recombinate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220-400 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">401-800 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">801-1240 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1241-1800 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1801-2400 unit (Price provided is per AHF Unit): $1.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135779\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Advate (AR, AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HK, HR, HU, IE, IS, IT, JP, KR, LT, MT, MY, NL, NO, NZ, PT, QA, RO, SE, SG, SI, SK);</li>\n      <li>Green Eight (KR);</li>\n      <li>Green VIII (LK);</li>\n      <li>Greenmono (KR);</li>\n      <li>Helixate (AT, GR, HU, IT, NL, PL);</li>\n      <li>Helixate Nexgen (AU, BE, CZ, DE, DK, EE, ES, FR, NO, SE);</li>\n      <li>Helixate NexGen (GB, IE);</li>\n      <li>Kogenate (AT, BE, CH, CL, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HR, HU, IE, IT, JO, LT, LU, MT, NL, NO, NZ, PL, PT, SE, SI, TW);</li>\n      <li>Kogenate FS (AE, AR, AU, CN, CO, CR, EC, GT, HK, HN, ID, IL, LB, MY, PA, QA, SA, SG, SV, TH, ZA);</li>\n      <li>Kryobulin TIM 3 (HN);</li>\n      <li>Logenate (RO);</li>\n      <li>Octanate (ID, MY);</li>\n      <li>Recombinate (AR, AT, AU, BE, BG, BR, CH, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IL, IT, LT, NL, NZ, QA, SE, TH);</li>\n      <li>Refacto (AT, CY, CZ, GR, HU, IT, NL, PL);</li>\n      <li>Refacto AF (BE, CH, DE, DK, EE, FR, GB, NO, SE);</li>\n      <li>Xyntha (AR, AU, CL, KR, NZ, SA, SG, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abshire TC, Brackmann HH, Scharrer I, et al, &ldquo;Sucrose Formulated Recombinant Human Antihemophilic Factor VIII is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy. International Kogenate-FS Study Group,&rdquo; <i>Thromb Haemost</i>, 2000, 83(6):811-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/10896230/pubmed\" target=\"_blank\" id=\"10896230\">10896230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batorova A, Holme P, Gringeri A, et al. Continuous infusion in haemophilia: current practice in Europe. <i>Haemophilia</i>. 2012;18(5):753-759.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/22530687/pubmed\" target=\"_blank\" id=\"22530687\">22530687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batorova A, Martinowitz U. Continuous infusion of coagulation factors. <i>Haemophilia</i>. 2002;8(3):170-177.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bray GL, Gomperts ED, Courter S, et al, &ldquo;A Multicenter Study of Recombinant Factor VIII (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A. The Recombinate Study Group,&rdquo; <i>Blood</i>, 1994, 83(9):2428-35. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/8167332 /pubmed\" target=\"_blank\" id=\"8167332 \">8167332 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dingli D, Gastineau DA, Gilchrist GS, Nichols WL, Wilke JL. Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. <i>Haemophilia</i>. 2002;8(5):629-634.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/12199670/pubmed\" target=\"_blank\" id=\"12199670\">12199670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly KM, Butler RB, Farace L, et al, &ldquo;Superior In Vivo Response of Recombinant Factor VIII Concentrate in Children With Hemophilia A,&rdquo; <i>J Pediatr</i>, 1997, 130(4):537-40. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/9108849 /pubmed\" target=\"_blank\" id=\"9108849 \">9108849 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liesner RJ, &ldquo;Prophylaxis in Haemophilic Children,&rdquo; <i>Blood Coagul Fibrinolysis</i>, 1997, 8(Suppl 1):S7-10. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/9351529/pubmed\" target=\"_blank\" id=\"9351529\">9351529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National  Hemophilia Foundation. MASAC recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). 2007. Available at http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac179.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poon MC, Card R. Hemophilia management in transfusion medicine. <i>Transfus Apher Sci</i>. 2012;46(3):299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/22503305/pubmed\" target=\"_blank\" id=\"22503305\">22503305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scharrer I, Bray GL, and Neutzling O, &ldquo;Incidence of Inhibitors in Haemophilia A Patients - A Review of Recent Studies of Recombinant and Plasma-Derived Factor VIII Concentrates,&rdquo; <i>Haemophilia</i>, 1999, 5(3):145-54. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/10444280 /pubmed\" target=\"_blank\" id=\"10444280 \">10444280 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shord SS and Lindley CM, &ldquo;Coagulation Products and Their Uses,&rdquo; <i>Am J Health Syst Pharm</i>, 2000, 57(15):1403-20. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/10938981/pubmed\" target=\"_blank\" id=\"10938981\">10938981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwartz RS, Abildgaard CF, Aledort LM, et al, &ldquo;Human Recombinant DNA-Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A. Recombinant Factor VIII Study Group,&rdquo; <i>N Engl J Med</i>, 1990, 323(26):1800-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/2123300/pubmed\" target=\"_blank\" id=\"2123300\">2123300</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/22776238/pubmed\" target=\"_blank\" id=\"22776238\">22776238</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12757 Version 163.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135784\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F135785\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051146\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11432529\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051139\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135770\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F135756\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573579\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051150\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F135782\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051149\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6814324\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135804\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135776\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135760\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819745\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298758\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218001\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135766\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F135778\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051145\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1051148\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135759\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F135775\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1051154\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F21121604\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F135779\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12757|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-viii-recombinant-human-drug-information\" class=\"drug drug_general\">Factor VIII, recombinant human: Drug information</a></li><li><a href=\"topic.htm?path=factor-viii-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">Factor VIII, recombinant human: Patient drug information</a></li></ul></div></div>","javascript":null}